Edition:
United Kingdom

Catalyst Pharmaceuticals Responds To Feb. 4 Letter From Senator Bernie Sanders


Thursday, 21 Feb 2019 

Feb 21 (Reuters) - Catalyst Pharmaceuticals Inc ::CATALYST PHARMACEUTICALS RESPONDS TO LETTER FROM SENATOR BERNIE SANDERS.CATALYST PHARMACEUTICALS INC - HAS RESPONDED TO FEBRUARY 4, 2019 LETTER THAT COMPANY RECEIVED FROM SENATOR BERNIE SANDERS.CATALYST PHARMA - BELIEVE PRICING OF FIRDAPSEG IS IN LINE WITH PRICING OF OTHER PRODUCTS PROVIDING SIGNIFICANT CLINICAL BENEFITS IN TREATING ULTRA-ORPHAN DISEASE OF SIMILAR SEVERITY.CATALYST PHARMA - BELIEVE PRICING OF FIRDAPSEG IN LINE TO COMPENSATE COS FOR COSTS OF DEVELOPING, MANUFACTURING, MARKETING ORPHAN DRUG IN COMPLIANCE WITH REGULATORY REQUIREMENTS.CATALYST PHARMA - BELIEVE DRUG WILL BE WIDELY COVERED, REIMBURSED BY PRIVATE & PUBLIC PAYERS FOR INDICATED SMALL POPULATION OF ADULT LEN-IS PATIENTS.CATALYST PHARMA- FORECASTED REBATES, DISCOUNTS, PATIENT COMMERCIAL CO-PAY SUPPORT, AMONG OTHERS, WILL RESULT IN NET SALE PRICE BEING 15-20% LOWER THAN ANNUAL LIST PRICE FOR PRODUCT.CATALYST PHARMA- FORECASTED MEDICARE COVERAGE GAP SUBSIDIES, STATUTORY MEDICAID DISCOUNTS WILL ALSO RESULT IN NET SALE PRICE BEING 15-20% LOWER THAN ANNUAL LIST PRICE FOR PRODUCT.CATALYST PHARMA- FORECASTED OTHER GOVERNMENTAL DISCOUNTS WILL ALSO RESULT IN NET SALE PRICE BEING 15-20% LOWER THAN ANNUAL LIST PRICE FOR PRODUCT.